CDKI-73 - CAS 1421693-22-2
Catalog number:
1421693-22-2
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H15FN6O2S2
Molecular Weight:
394.45
COA:
Inquire
Targets:
CDK
Description:
CDKI-73 was cytotoxic to all of the CLL samples tested (n = 38) with a mean LD50 value of 0.08μM ± 0.10 μM following exposure to drug for 48h. In contrast, normal B-lymphocytes (n = 10) and CD34+ normal bone marrow cells (n = 5) were significantly less susceptible to the cytotoxic effects of CDKI-73. Treatment of CLL cells with 0.1 μM CDKI-73 for 4h inhibited the phosphorylation of cdk9 and ser2 of RNA polymerase II. CDKI-73 induces a rapid loss of MCL1 protein and this is mediated by significant inhibition at the level of gene transcription. However, this inhibition is not restricted to MCL1 as similar reductions in XIAP and CCND2 were also observed following exposure to CDKI-73 for 4h. CDKI-73 rapidly inhibited cellular CDK9 kinase activity and down-regulated the RNAPII phosphorylation. CDK9 shRNA was also found to down-regulate the Mnk1 expression. Both CDKI-73 and CDK9 shRNA decreased anti-apoptotic proteins Mcl-1 and Bcl-2 and induced apoptosis. CDKI-73 exhibited a favorable pharmacokinetic profile with oral bioavailability of F = 56% following a single intravenous bolus dose at 2 mg/kg and an oral dose at 10 mg/kg in mice.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CDKI-73
MSDS:
Inquire
1.Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.
Lam F1, Abbas AY2, Shao H2, Teo T1, Adams J1, Li P1, Bradshaw TD2, Fischer PM2, Walsby E3, Pepper C3, Chen Y4, Ding J4, Wang S5. Oncotarget. 2014 Sep 15;5(17):7691-704.
Dysregulation of cellular transcription and translation is a fundamental hallmark of cancer. As CDK9 and Mnks play pivotal roles in the regulation of RNA transcription and protein synthesis, respectively, they are important targets for drug development. We herein report the cellular mechanism of a novel CDK9 inhibitor CDKI-73 in an ovarian cancer cell line (A2780). We also used shRNA-mediated CDK9 knockdown to investigate the importance of CDK9 in the maintenance of A2780 cells. This study revealed that CDKI-73 rapidly inhibited cellular CDK9 kinase activity and down-regulated the RNAPII phosphorylation. This subsequently caused a decrease in the eIF4E phosphorylation by blocking Mnk1 kinase activity. Consistently, CDK9 shRNA was also found to down-regulate the Mnk1 expression. Both CDKI-73 and CDK9 shRNA decreased anti-apoptotic proteins Mcl-1 and Bcl-2 and induced apoptosis. The study confirmed that CDK9 is required for cell survival and that ovarian cancer may be susceptible to CDK9 inhibition strategy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


CAS 902156-99-4 NVP-LCQ195

NVP-LCQ195
(CAS: 902156-99-4)

NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...

CAS 942425-68-5 PHA-767491 hydrochloride

PHA-767491 hydrochloride
(CAS: 942425-68-5)

PHA-767491 hydrochloride is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor, which prevents initiation of DNA replication. It inhibits cell proliferation in ...

Senexin A
(CAS: 1366002-50-7)

Senexin A is a selective Cell division protein kinase 8 (CDK8) inhibitor with IC50 value of 280 nM. Senexin A can bind to cdk19 in an ATP-competitive manner and...

CAS 212779-48-1 NG 52

NG 52
(CAS: 212779-48-1)

NG 52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respec...

CAS 827022-33-3 Palbociclib

Palbociclib
(CAS: 827022-33-3)

Palbociclib is a potent Cdk4/6 inhibitor.

CAS 1070790-89-4 CYC065

CYC065
(CAS: 1070790-89-4)

CYC065 is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with potential antineoplastic and chemoprotective activities.

CAS 211555-08-7 WHI-P180

WHI-P180
(CAS: 211555-08-7)

WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...

CAS 827022-32-2 Palbociclib HCl

Palbociclib HCl
(CAS: 827022-32-2)

Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic acti...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 1604810-83-4 THZ1

THZ1
(CAS: 1604810-83-4)

THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine ...

CAS 496864-16-5 Aloisine A

Aloisine A
(CAS: 496864-16-5)

Aloisine a is a cell-permeable pyrrolo-pyrazine compound that acts as a potent, selective, reversible, and ATP-competitive inhibitor of cyclin dependent kinases...

CAS 1263369-28-3 CDK9-IN-2

CDK9-IN-2
(CAS: 1263369-28-3)

CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.

CAS 1421693-22-2 CDKI-73

CDKI-73
(CAS: 1421693-22-2)

CDKI-73 was cytotoxic to all of the CLL samples tested (n = 38) with a mean LD50 value of 0.08μM ± 0.10 μM following exposure to drug for 48h. In contrast, norm...

CAS 1231929-97-7 Abemaciclib

Abemaciclib
(CAS: 1231929-97-7)

Abemaciclib is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potentia...

CAS 902135-91-5 AT7519 HCl

AT7519 HCl
(CAS: 902135-91-5)

KH-CB19
(CAS: 1354037-26-5)

KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.

THZ2
(CAS: 1604810-84-5)

THZ2, an analog of THZ1, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor which overcomes the insta...

CGP74514A
(CAS: 190653-73-7)

CGP74514A is a cell permeable Cdk inhibitor selective for Cyclin-dependent kinase-1 (Cdk1) (IC50=25nM). CGP74514A was also reported also to affect the activitie...

CAS 1453834-21-3 LDC4297

LDC4297
(CAS: 1453834-21-3)

LDC4297 is a potent and selective cyclin-dependent protein kinase 7 (CDK7) inhibitor with an IC50 of 0.13 nM.

CAS 1269815-17-9 CDK-IN-2

CDK-IN-2
(CAS: 1269815-17-9)

CDK-IN-2 is a potent and sepecific CDK inhibitor.

Chemical Structure

CAS 1421693-22-2 CDKI-73

Quick Inquiry

Verification code

Featured Items